Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | HTR2B | P41595 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.54 |
| ▸ | HTR1A | P08908 | 6/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125994 | 1.00 | HTR2C (0.59) | HTR2CHTR2BSLC6A2HTR1ACHRNB2 | |
| SCHEMBL4700578 | 1.00 | HTR2C (0.59) | HTR2CHTR2BSLC6A2HTR1ACHRNB2 | |
| Hydrochloric Acid SCHEMBL28313668 | 0.98 | HTR2C (0.58) | HTR2CHTR2BSLC6A2HTR1ACHRNB2 | |
| Hydrochloric Acid SCHEMBL28313667 | 0.98 | HTR2C (0.58) | HTR2CHTR2BSLC6A2HTR1ACHRNB2 | |
| SCHEMBL19582779 | 0.89 | CHRNB2 (0.55) | HTR2CHTR2BSLC6A2HTR1ACHRNB2 | |
| SCHEMBL15650257 | 0.89 | CHRNB2 (0.55) | HTR2CHTR2BSLC6A2HTR1ACHRNB2 | |
| SCHEMBL187435 | 0.89 | HRH1 (0.66) | HTR2CHTR2BSLC6A2HTR1AHRH1 | |
| SCHEMBL17593299 | 0.88 | CHRNB2 (0.50) | HTR2CHTR2BSLC6A2HTR1ACHRNB2 | |
| Hydrochloric Acid SCHEMBL15649585 | 0.88 | CHRNB2 (0.54) | HTR2CHTR2BSLC6A2HTR1ACHRNB2 | |
| Hydrochloric Acid SCHEMBL2776364 | 0.87 | HRH1 (0.63) | HTR2CHTR2BSLC6A2HTR1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038930-A1 | AZEPANE AND PYRROLIDINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS, INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
| EP-1791815-B1 | PYRROLIDINE DERIVATIVES ACTING AS CCR3-RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| EP-1791815-B1 | PYRROLIDINE DERIVATIVES ACTING AS CCR3-RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7754758-B2 | Pyrrolidine derivatives acting as CCR3-receptor antagonists | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| CN-1910145-B | Pyrrolidine derivatives acting as CCR3-receptor antagonists | NOVARTIS AG | 2010-06-16 | — | — | CN | disclosed |
| US-20090306138-A1 | PYRROLIDINE DERIVATIVES ACTING AS CCR3-RECEPTOR ANTAGONISTS | NOVARTIS PHARMA GMBH (AT) | 2009-12-10 | — | — | US | disclosed |
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1791815-A2 | PYRROLIDINE DERIVATIVES ACTING AS CCR3-RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| CN-1910145-A | Pyrrolidine derivatives acting as CCR3-receptor antagonists | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| WO-2005075420-A2 | PYRROLIDINE DERIVATIVES ACTING AS CCR3-RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | HTR2C 3/4885HTR2B 10/4885SLC6A2 5/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | HTR2C 3/4885HTR2B 10/4885SLC6A2 5/4885 |
| US-20090306138-A1 | PYRROLIDINE DERIVATIVES ACTING AS CCR3-RECEPTOR ANTAGONISTS | CCR3, CCR1, CCR4 | HTR2C 1960/4885HTR2B 1827/4885SLC6A2 3352/4885 |
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | HTR2C 3927/4885HTR2B 4192/4885SLC6A2 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.